Current indications for ocular photodynamic therapy – A review of the literature and two case reports

Medical laser application : international journal for laser treatment and research Pub Date : 2010-11-01 DOI:10.1016/j.mla.2010.07.003

Lieselotte Berger, Ute Wolf-Schnurrbusch, Christian Brinkmann, Sebastian Wolf

{"title":"Current indications for ocular photodynamic therapy – A review of the literature and two case reports","authors":"Lieselotte Berger, Ute Wolf-Schnurrbusch, Christian Brinkmann, Sebastian Wolf","doi":"10.1016/j.mla.2010.07.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Presentation of the current treatment indications for photodynamic therapy (PDT) with verteporfin in the management of different choroidal diseases.</p></div><div><h3>Methods</h3><p>A review is given of the standard treatment protocol, the results of published clinical trials and cohort or case-control studies with two clinical examples.</p></div><div><h3>Results</h3><p>Monotherapy with PDT for neovascular age-related macular degeneration is no longer a first-line therapy. The reasoning behind combining PDT with an antiangiogenic treatment with anti-vascular endothelial growth factor is to decrease the number of re-treatments. In other diseases of the choroid, such as circumscribed choroidal hemangioma or central serous chorioretinopathy, use of PDT with verteporfin as a monotherapy may prove to be an effective method to improve or stabilize vision in the majority of patients.</p></div><div><h3>Conclusions</h3><p>Verteporfin PDT still represents an effective and safe treatment because of its selectivity to the choroid.</p></div>","PeriodicalId":88584,"journal":{"name":"Medical laser application : international journal for laser treatment and research","volume":"25 4","pages":"Pages 235-241"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.mla.2010.07.003","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical laser application : international journal for laser treatment and research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1615161510000682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Background

Presentation of the current treatment indications for photodynamic therapy (PDT) with verteporfin in the management of different choroidal diseases.

Methods

A review is given of the standard treatment protocol, the results of published clinical trials and cohort or case-control studies with two clinical examples.

Results

Monotherapy with PDT for neovascular age-related macular degeneration is no longer a first-line therapy. The reasoning behind combining PDT with an antiangiogenic treatment with anti-vascular endothelial growth factor is to decrease the number of re-treatments. In other diseases of the choroid, such as circumscribed choroidal hemangioma or central serous chorioretinopathy, use of PDT with verteporfin as a monotherapy may prove to be an effective method to improve or stabilize vision in the majority of patients.

Conclusions

Verteporfin PDT still represents an effective and safe treatment because of its selectivity to the choroid.

查看原文本刊更多论文

目前眼光动力治疗的适应症-文献回顾和两个病例报告

背景介绍目前使用维替泊芬光动力治疗(PDT)治疗不同脉络膜疾病的适应症。方法对标准治疗方案、已发表的临床试验和队列或病例对照研究结果进行综述，并结合两个临床实例。结果单药PDT治疗新生血管性年龄相关性黄斑变性不再是一线治疗方法。PDT与抗血管内皮生长因子联合抗血管生成治疗的原因是减少再治疗的次数。在其他脉络膜疾病中，如局限性脉络膜血管瘤或中枢性浆液性脉络膜视网膜病变，PDT联合维替泊芬作为单药治疗可能被证明是改善或稳定大多数患者视力的有效方法。结论维替波芬对脉络膜有选择性，是一种安全有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical laser application : international journal for laser treatment and research

自引率

0.00%

发文量